Should I wait for creatinine before this CT?

Good posts start with good questions. Have an ER question? Send it here.

KEY

🔍- Deep Dive

📌- Clinical Application

🔸 - Weak Evidence

🔹 - Strong Evidence

📑 - Evidence summaries

✅ - Recommended treatment

⚠️ - Critical Information

This article comes from a mistake I made. Or maybe a mistake I keep making regularly.

Waiting.

Waiting for a creatinine report before sending a patient for a contrast-enhanced CT in the emergency department. Because what if I cause contrast nephropathy? So I went down a rabbit hole. And what I found surprised me.

👉

Jump to what matters ⏬

Where did this fear even come from?

The idea of contrast nephropathy dates back to the 1950s, when patients developed renal failure after contrast studies like intravenous pyelography. But back then, contrast agents were very different. Also, evidence-based medicine wasn’t really a thing yet. But the idea stuck.

Once the myth took hold, we started labelling every rise in creatinine after a contrast CT as “contrast-induced nephropathy.” But in reality, that rise could have been due to a multitude of other factors.

We assumed causation without actually proving it.

📑

A large meta-analysis found no significant difference in AKI between contrast and non-contrast CT scans, suggesting that patient-related factors, not contrast, are more likely responsible 1

What even is “Contrast Nephropathy”?

Traditionally, contrast nephropathy was defined as any increase in creatinine after contrast exposure

The underlying assumption? Even a small bump in creatinine must represent real kidney injury, and it actually matters clinically.

But that assumption is questionable.

Modern definitions are more cautious. Over time, experts realised we were being a bit too confident about causation.

🔍

KDIGO proposed the term “contrast-induced acute kidney injury (CI-AKI)” and defined it as a rise in serum creatinine of ≥0.5 mg/dL (44 μmol/L) or a ≥25% increase from baseline, measured within 48 hours of a contrast study.

But these definitions only tell us what happened, not why it happened.

But later, KDIGO introduced the term “Contrast-associated acute kidney injury”, accepting that in many cases AKI may or may not be solely attributable to contrast. 2

While AKI itself is defined as

Functional criteria	Structural criteria
• Increase in SCr by ≥0.3 mg/dl within 48 hours • Increase in SCr or serum cystatin C by ≥1.5 times baseline, that is known/presumed to have occurred within the prior 7 days • Mean urine volume of less than 0.5 ml/kg/h for ≥6 hours	Elevation of a biomarker of kidney damage which ismknown or presumed to have occurred within the prior 7 days

The American College of Radiology (ACR) also agree that we stop using the term contrast-induced nephropathy (CIN) so casually. They made the important distinction that CI-AKI is a causative diagnosis while CA-AKI is a correlative diagnosis 3.

⚠️

The important shift: correlation ≠ causation

So, is contrast nephropathy real?

Unfortunately, it would be unethical to perform a true prospective RCT to definitively answer this question. But over the past decade, numerous studies and meta-analyses have emerged, and most of them don’t find any meaningful relationship between contrast administration and kidney injury.

To really answer the question of contrast nephropathy, we need to ask three things:

1. Does contrast increase creatinine?

📑

Across multiple large studies:

No difference in AKI, dialysis, or mortality between contrast and non-contrast CT groups

Pre-existing chronic kidney disease is the strongest patient-related risk factor. However, even in this group, intravenous contrast was not associated with an increased risk of AKI.

Same findings in sepsis, critically ill patients and the ED population.

A meta-analysis even showed similar AKI rates in contrast and non-contrast CT, suggesting other factors are responsible. [17-18]

Some studies do report a small signal. There appears to be a minimal risk of CIN in mild to moderate renal dysfunction [19]

2. Does that increased creatinine really reflect renal injury?

📑

This is where things get even more interesting [1322]

Creatinine fluctuates naturally, even without contrast

Studies show no change in kidney injury biomarkers (KIM-1, NGAL) after contrast

In the many cohorts, the mean creatinine doesn’t change [1820-21]

Which is interesting because if the average doesn’t change, but a few patients go up, a few must also be going down. This starts to look less like pathology and more like random fluctuation.

Interestingly, KDIGO provides a detailed list of nephrotoxins. Contrast isn’t explicitly mentioned. But many drugs we use quite casually are:

Trimethoprim

Cimetidine

Corticosteroids

Cephalosporins

Colistin

Vancomycin

PPIs

NSAIDs

Acyclovir

Diuretics

We worry a lot about the contrast of a theoretical nephrotoxin. But routinely prescribe drugs that are well-established nephrotoxins. That mismatch is worth thinking about.

3. Does it actually affect patient outcomes?

📑

Even if creatinine rises [7, 152023]

No increase in dialysis rates

No increase in mortality

No worsening of clinical outcomes

Even in patients with pre-existing CKD, contrast was not associated with worse outcomes.

ACR (2025) notes that when creatinine does rise after contrast, the course is usually mild and transient. It begins within 24 hours, peaks by around day 4 and returns to baseline within 7–10 days. Permanent renal dysfunction is unusual.

Is there a pathophysiological basis?

The exact mechanism by which contrast might cause kidney injury is not entirely clear. But a few theories do exist. 4

Direct toxicity: Contrast agents are thought to have a direct toxic effect on tubular epithelial cells. This can lead to: loss of function, apoptosis or even necrosis.

Indirect Injury: A lot of the proposed injury is actually indirect. Contrast can cause vasomotor changes mediated by substances like endothelin, nitric oxide and prostaglandins. This leads to reduced renal blood flow and, consequently, ischemia. Since the outer medulla of the kidney already lives on the edge, with low oxygen tension and high metabolic demand, even small hemodynamic changes can tip it into injury.

While all of this sounds convincing. We must know that these mechanisms are theoretical and lab-based and don’t consistently translate into clinically significant injury in real patients

Also, all contrasts are not the same

There are three categories of iodinated contrast:

High-osmolar contrast (~1500 mOsm)
Diatrizoate (Hypaque, Gastrografin), iothalamate

Low-osmolar contrast (320–800 mOsm)
Iohexol, ioxaglate, ioversol, iomeprol, iopromide, iopamidol

Iso-osmolar contrast (~290 mOsm)
Iodixanol

Although we don’t have placebo-controlled trials proving the existence of CIN, we do have randomised trials comparing these agents with each other.

🔹 Compared to older high-osmolar contrast agents, modern low- and iso-osmolar agents are associated with a lower risk of kidney injury. Because of this, their use is strongly recommended by major societies, including the ESC and AHA–ACC.

While ACR and the National Kidney Foundation say

There are no confirmed clinically relevant differences in risk of CA-AKI between low-osmolality contrast media and iso-osmolarity contrast media for intravenous applications.

📑

A network meta-analysis of 42 trials (over 10,000 patients) looked at this and found that Iohexol and ioxaglate had higher rates of kidney injury. Around 11% incidence with these agents vs ~6% with others [5]

Another meta-analysis compared iodixanol (iso-osmolar) with low-osmolar agents and showed no overall reduction in AKI risk with iodixanol, but a subgroup suggested worse outcomes with iohexol. But this finding was largely driven by a single study [6]

Which brings us back to the bigger question: Are we comparing small differences in risk for a problem that may not even be clinically significant?

What about CKD patients?

Interestingly, contrast-associated AKI has been linked to increased mortality and progression of CKD. The ACR and the National Kidney Foundation suggest that

The risk of CA-AKI increases with each stepwise increase in CKD stage

The risk of CI-AKI is substantially less than the risk of CA-AKI, but the actual risk remains uncertain in patients with severe kidney disease.

ACR guidance on using contrast in CKD patients is this

Patients with anuric end-stage kidney disease can receive contrast without risk of further renal damage because there’s essentially no residual kidney function to lose.

But there’s a nuance. In patients who are not completely anuric (still making urine):

There is a theoretical risk of pushing them from oliguric → anuric
But this remains unproven and speculative
So practically: Patients on dialysis who still make >200–400 mL urine/day should be treated as high-risk.

But do not start dialysis or change dialysis schedules just because contrast was given. There is no proven benefit, and it only adds risk and cost.

We will probably never be able to prove with 100% certainty that contrast isn’t nephrotoxic, which would require an impractical RCT. But based on current evidence, if it is nephrotoxic at all, it is likely an extremely weak nephrotoxin with little clinical relevance.

⚠️

Hence, the ACR / National Kidney Foundation guidance states that patients with CKD stages 4 or 5 have a relative rather than an absolute contraindication to iodinated contrast media. If contrast media administration is required for a life-threatening diagnosis, then it should not be withheld based on kidney function

Risk–benefit balance

So it really comes down to this, balancing the risk vs benefit of giving IV contrast for a CT.

ACR says there is no agreed-upon threshold of serum creatinine elevation or eGFR decline beyond which the risk of CI-AKI is considered so great that intravascular iodinated contrast medium should never be administered. In fact, since each contrast medium administration always implies a risk-benefit analysis for the patient, contrast medium administration for all patients should always be taken in the clinical context, considering all risks, benefits and alternatives.

Right now, that calculation looks like:

Risk of contrast: No strong, high-quality evidence that this risk meaningfully exists

Benefit of contrast: Often immediate, real, and clinically important

✅

ACR 2025 guidance suggests renal function assessment before the intravascular administration of iodinated contrast medium for these patients when done in the ED

Personal history of renal disease

History of diabetes mellitus (optional)

Metformin or metformin-containing drug combinations

Ignoring the harms of not using contrast

We can’t talk about the harms of contrast without also talking about the harms of not using it. We often withhold essential tests because of the fear of CIN. Patients with CKD get non-contrast scans when contrast was actually needed, or we order V/Q scans when a CTPA would have been the better test. We don’t have great numbers to quantify this harm, but it clearly exists.

There’s also the system-level cost. Patients wait, often for hours, for creatinine results before getting a scan. That delay can mean delayed diagnosis and delayed treatment. And even when it doesn’t, it adds to ED crowding and keeps patients longer in an already stressful environment.

Now that we know all this… we will probably still wait for the creatinine. Because as doctors, we are wired to be risk-averse.

So here is what we can do

Step 1: Confirm the indication

Ask a simple question first: Will contrast change diagnosis or management?

It's important to remember ACR guidance here

Even in high-risk patients (AKI or eGFR <30 not on dialysis), concern for CI-AKI is a relative, not absolute contraindication to contrast. If alternative imaging (non-contrast CT, ultrasound, MRI) can answer the question, then contrast can be avoided. But in some situations, contrast is necessary regardless of CI-AKI risk.

If contrast media administration is required for a life-threatening diagnosis, then it should not be withheld based on kidney function

If it is a time-critical emergency scan where there is no reasonable alternate modality, proceed with the contrast study; do not wait for the creatinine report

Step 2: Assess risk

Risk is not a single number. It comes from a combination of patient and procedural factors.

Patient-related factors	Procedure-related factors
Reduced GFR (especially <30 mL/min/1.73 m²)	High-osmolar contrast
Diabetes mellitus	Large volume of contrast
Hypovolemia	Serial contrast exposure
Concurrent nephrotoxic medications	Intra-arterial administration

One of the ways to approach and stratify risk is the use of the Choyke questionnaire to identify patients with a higher risk of abnormal renal function

Has any doctor ever told you that you have kidney problems?

Has any doctor ever told you that you have protein in your urine (proteinuria)?

Do you have high blood pressure (hypertension)?

Do you have diabetes?

Do you have gout?

Have you ever had kidney surgery?

📑

CW too et al concluded that the Choyke questionnaire has excellent sensitivity and moderate-to-good specificity in detecting patients with <45mL/min/1.73m2; below this level, it has been shown that the risk of contrast-induced nephropathy increases significantly, making it an effective screening tool. [24]

⚠️

One important caveat: PCI has its own separate risk scoring system.

Once risk is assessed, patients broadly fall into three groups:

Low risk - Proceed with the scan.

Intermediate to high risk -

If benefit > harm → proceed (with appropriate precautions if needed)
If harm > benefit → consider alternative imaging or strategies

Basically, you are asking: “Is this scan important enough to justify the risk?”

Step 3: What can we do to reduce risk?

1. Choice of iodinated contrast media

Use Iso-osmolar or Low-osmolar contrast media (KIDGO 2026)

Use the lowest possible dose required for adequate imaging (KIDGO 2026)

2. Volume expansion

Initiate peri-procedural volume expansion with 0.9% NS before contrast study if feasible (KIDGO 2026)
No high certanity evidence.
However, in the dehydrated state, renal blood flow and GFR are decreased, the effect of iodinated contrast medium may be accentuated, and there is a theoretical concern of prolonged tubular exposure to iodinated contrast medium due to low tubular flow rates.

3. Other aspects (KIDGO 2026)

Withhold all non-essential nephrotoxic drugs

Other drugs that have been considered but not found to be useful are

N-acetylcysteine
Ascorbic acid
Furosemide
Dopamine
Fenoldopam
Calcium channel blockers
Sodium bicarbonate

Prophylactic hemodialysis is potentially harmful

What Matters…

Before deciding to wait for a creatinine report to do a CT in the ED, ask these questions

1️⃣ Is it an emergency scan?

If contrast media administration is required for a life-threatening diagnosis, then it should not be withheld based on kidney function

2️⃣ Is there an indication to do creatinine?

ACR 2025 guidance suggests renal function assessment before the intravascular administration of iodinated contrast medium for these patients when done in the ED

Personal history of renal disease

History of diabetes mellitus (optional)

Metformin or metformin-containing drug combinations

Since many ED patients are unaware of their renal status, consider using the Choyke questionnaire to identify patients with a higher risk of abnormal renal function

Has any doctor ever told you that you have kidney problems?

Has any doctor ever told you that you have protein in your urine (proteinuria)?

Do you have high blood pressure (hypertension)?

Do you have diabetes?

Do you have gout?

Have you ever had kidney surgery?

If any of these is true, it is reasonable to wait for the creatinine report.

3️⃣Is the patient anuric?

Patients with anuric end-stage kidney disease can receive contrast without risk of further renal damage because there’s essentially no residual kidney function to lose.

If not → it is important to remember that CKD is only a relative contraindication to contrast-enhanced scans.